Capricor Stock Rallies 20% on DMD Data Presentation Update
Wave Life Sciences Is Maintained at Sector Perform by RBC Capital
RBC Raises Price Target on WAVE Life Sciences to $7 From $5, Keeps Sector Perform Rating, Speculative Risk
B.Riley Financial Maintains Wave Life Sciences(WVE.US) With Buy Rating, Raises Target Price to $19
B. Riley Adjusts WAVE Life Sciences' PT to $19 From $11, Maintains Buy Rating
Better Biotech Stock: Wave Life Sciences Vs. Sarepta Therapeutics
GSK Plc Acquires $22.3 Million Worth of Wave Life Sciences Shares
Wave Life Sciences Showcases RNA Pipeline and Collaborations
Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference
Wave Put on J.P. Morgan Positive Catalyst Watch Ahead of Data Readout
WAVE Life Sciences Analyst Ratings
J.P. Morgan Maintains Wave Life Sciences(WVE.US) With Buy Rating, Raises Target Price to $13
Express News | Wave Life Sciences Ltd : JP Morgan Resumes Coverage With Overweight Rating; Target Price $13
Reported Earlier, Wave Life Sciences Raised $200M Via Secondary Stock Offering Of 23.1M Shares At $8/Share
Wave Life Sciences Offering Expected to Close Around Sept. 27 >WVE
Express News | Wave Life Sciences - Pricing of Its Previously Announced Underwritten Public Offering of 23.12 Mln at a Price to Public of $8.00 per Ordinary Share
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Press Release: Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Mizuho Securities Maintains Wave Life Sciences(WVE.US) With Buy Rating
Wave Life Sciences' Strong Clinical Data and Market Potential Merit Buy Rating